Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
RNA Sequencing Analysis for the Identification of a PCM1/PDGFRB Fusion Gene Responsive to Imatinib.
Such E, Liquori A, Mora E, Marco-Ayala J, Avetisyan G, Regadera A, Ibañez F, Panadero J, Senent L, Llop M, Díaz A, Vicente A, Luna I, Ibáñez M, Barragán E, Sanz MA, Sanz G, Communidad Valenciana, Cervera J. Such E, et al. Among authors: marco ayala j. Acta Haematol. 2019;142(2):92-97. doi: 10.1159/000497348. Epub 2019 May 14. Acta Haematol. 2019. PMID: 31085913
Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain.
Solana-Altabella A, Boluda B, Rodríguez-Veiga R, Cano I, Acuña-Cruz E, Blanco A, Marco-Ayala J, de la Puerta R, Díaz-González Á, Piñana JL, Sanz J, Sempere A, Cervera J, Barragán E, Sargas C, Ballesta-López O, Megías-Vericat JE, Martínez-Cuadrón D, Sanz MÁ, Montesinos P. Solana-Altabella A, et al. Among authors: marco ayala j. Eur J Haematol. 2021 May;106(5):724-733. doi: 10.1111/ejh.13604. Epub 2021 Mar 5. Eur J Haematol. 2021. PMID: 33609315
Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.
Boluda B, Martínez-Cuadrón D, Algarra L, Cano I, Sayas MJ, Acuña-Cruz E, Blanco A, Marco-Ayala J, DeLapuerta R, Díaz-González Á, Tormo M, Rodríguez-Veiga R, García R, Piñana JL, López-Pavía M, Barragán E, Amigo ML, Sargas C, López A, Solana-Altabella A, Gil C, Megías-Vericat JE, Sanz MA, Montesinos P. Boluda B, et al. Among authors: marco ayala j. Leuk Lymphoma. 2021 Nov;62(11):2727-2736. doi: 10.1080/10428194.2021.1938031. Epub 2021 Jun 14. Leuk Lymphoma. 2021. PMID: 34121593
NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy.
Hurtado-Navarro L, Cuenca-Zamora EJ, Zamora L, Bellosillo B, Such E, Soler-Espejo E, Martínez-Banaclocha H, Hernández-Rivas JM, Marco-Ayala J, Martínez-Alarcón L, Linares-Latorre L, García-Ávila S, Amat-Martínez P, González T, Arnan M, Pomares-Marín H, Carreño-Tarragona G, Chen-Liang TH, Herranz MT, García-Palenciano C, Morales ML, Jerez A, Lozano ML, Teruel-Montoya R, Pelegrín P, Ferrer-Marín F. Hurtado-Navarro L, et al. Among authors: marco ayala j. Cell Rep Med. 2023 Dec 19;4(12):101329. doi: 10.1016/j.xcrm.2023.101329. Cell Rep Med. 2023. PMID: 38118408 Free PMC article.
Impact of Post-Transplantation Cyclophosphamide on Transfusion Requirements in HLA-Matched Sibling Peripheral Blood Stem Cell Transplantation.
Marco-Ayala J, Sanz J, Gómez-Seguí I, Balaguer-Rosello A, Montoro J, Guerreiro M, Chorao P, Facal A, Villalba M, Sanz MÁ, de la Rubia J, Solves P. Marco-Ayala J, et al. Transplant Cell Ther. 2023 May;29(5):313.e1-313.e10. doi: 10.1016/j.jtct.2023.01.009. Epub 2023 Jan 14. Transplant Cell Ther. 2023. PMID: 36646324 Free article.